Puma Biotechnology Investor Presentation — August 2020

Document content

Forward -Looking Safe Harbor Statement

2This presentation contains forward -looking statements, including statements regarding thetiming ofexpected

launch andexpected regulatory approvals forNERLYNX® .Allstatements other than historical facts areforward–

looking statements andarebased onthecurrent expectations, forecasts andassumptions ofPuma Biotechnology,

Inc.(“Puma”) .Forward–looking statements involve risks anduncertainties thatcould causePuma’s actual results

todiffer materially from theanticipated results andexpectations expressed inthese forward -looking statements,

including, butnotlimited to,anyadverse impact onPuma’s business ortheglobal economy andfinancial markets,

generally, from theglobal COVID -19pandemic, andother riskfactors disclosed intheperiodic andcurrent reports

filed byPuma withtheSecurities andExchange Commission from time totime, including Puma’s Annual Report on

Form 10-Kfortheyear ended December 31,2019 ,Puma’s Quarterly Report onForm 10-Qfortheperiod ended

June 30,2020 andsubsequent reports .You arecautioned nottoplace undue reliance onthese forward -looking

statements, which speak only asofthedate hereof, andyoushould notrelyonthese forward -looking statements

asrepresenting Puma’s views asofanydate subsequent tothedate ofthispresentation .Puma assumes no

obligation toupdate these forward -looking statements, except asrequired bylaw.3

PatientsPUMA’s Pharmacy and Distributor Network

Others (VA, DOD)Hub Services

Specialty Pharmacy Network (SP)

Specialty Distributor Network (SD)

ASD/Oncology supply4

~$48.8 Million Net NERLYNX Revenue in Q2’2020

Q3 2017 Q4 2017 Q1 2018 Q2 2018 Q3 2018 Q4 2018 Q1 2019 Q2 2019 Q3 2019 Q4 2019 Q1 2020 Q2'2020Quarterly Net Revenue (in $MM)